3-Step APRISO™ Reimbursement Information
This free support service helps patients with Inflammatory Bowel Disease (IBD) get answers to third
party payer coverage questions for APRISO. Our staff can also negotiate appeals on behalf of your patients
should their claims be denied. The Helpline can also provide a timely solution to issues you may encounter
either before or after submitting a patient claim for reimbursement, such as:
- Receive current reimbursement policies for private payers, Medicaid, and Medicare
- Verify individual patient coverage
- Conduct prior authorizations
- Manage negotiation of appeals on denied claims
- Receive customized information to assist with coverage or appeals
Step 1. Fill out the Form
Download the Patient Information Form and fill it out
APRISO Helpline Form (MS-Word)
For easy-to-follow instructions and an example of a filled-out Patient Information Form,
click below to view our brochure, "Completing the Patient Information Form."
APRISO Informational Brochure (PDF 1.4MB)
Step 2. Get Questions Answered
For questions regarding the Patient Information Form and reimbursement support, call the Helpline.
IBD Reimbursement Helpline
1-800-444-DRUG
1-800-444-3784
- Trained reimbursement analysts can answer your questions
- Open Monday through Friday, 8:30 AM to 5:30 PM Eastern Standard Time
Step 3. Submit the Completed Form
Completed Patient Information Forms must be submitted via this fax number
IBD Reimbursement Fax Line
1-800-387-5807
Get Adobe Acrobat Reader
APRISO™ is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older.
APRISO is contraindicated in patients with hypersensitivity to salicylates, aminosalicylates, or to any of the components of APRISO capsules.
The recommended dose of APRISO is four 0.375 g capsules once daily in the morning (1.5 g/day) with or without food. Because dissolution of the coating of APRISO
granules depends on pH, APRISO should not be coadministered with antacids. Patients with phenylketonuria should be aware that APRISO contains aspartame,
equivalent to 0.56 mg of phenylalanine. In two well-controlled clinical trials, the most common treatment-related adverse events occurring in at least 3%
of adult patients taking 1.5 g/day of APRISO were headache (11% vs. 8% for placebo), diarrhea (8% vs. 7% for placebo), upper abdominal pain (5% vs 3% for placebo),
nausea (4% vs 3% for placebo), nasopharyngitis (4% vs 3% for placebo), influenza and influenza-like illness (4% vs 4% for placebo) and sinusitis (3% vs 3% for placebo).
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: